当前静脉曲张治疗的成本效果分析
该研究更新系统综述并构建马尔可夫决策模型,分析保守治疗、手术、UGFS、EVLA、RFA、MOCA和CAE治疗静脉曲张5年内的效果与成本效果。结果显示EVLA最具成本效果,RFA次之;UGFS再干预率显著更高,MOCA、UGFS、CAE、保守治疗和手术在英國NHS现行价格下不具成本效果。
要点
- EVLA是需求治疗的大隐静脉功能不全成人患者中最具成本效果的选择,RFA次之。
- UGFS再干预率显著高于其他操作,其余操作间无显著差异。
- MOCA和CAE具前景,但需更多效果、再干预和生活质量证据。
核心结论
- EVLA是需求治疗的大隐静脉功能不全成人患者中最具成本效果的治疗选择,RFA紧随其后。
- MOCA、UGFS、CAE、保守治疗和高位结扎剥脱术在英國NHS现行价格下不具成本效果。
研究设计与样本
- 更新系统综述并构建马尔可夫决策模型,评估5年内的再干预、残留静脉曲张再治疗、QALY和成本。
主要发现
- UGFS再干预率显著高于其他操作,其他操作间无显著差异。
- EVLA对比UGFS的每QALY成本为£16,966($23,700),在英國被认为具成本效果。
- RFA、MOCA和CAE的操作成本高于EVLA,且无证据显示患者获益更大。
关键数值与推荐
- EVLA vs UGFS的每QALY成本为£16,966($23,700)。
- UGFS再干预率显著高于其他操作。
- RFA、MOCA和CAE操作成本高于EVLA,无更大获益证据。
临床怎么用
- 在英國NHS背景下,优先选择EVLA治疗大隐静脉功能不全,RFA可作为次选。
- MOCA和CAE暂不推荐作为具成本效果的选择,需等待更多证据。
局限性
- MOCA和CAE的效果、再干预和健康相关生活质量证据仍需进一步研究。
- 成本效果可能因环境和报销体系不同而变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the effectiveness and cost effectiveness of technologies for treatment of varicose veins over 5 years-conservative care, surgery (high ligation and stripping), ultrasound-guided foam sclerotherapy (UGFS), endovenous laser ablation (EVLA), and radiofrequency ablation (RFA), mechanochemical ablation (MOCA), and cyanoacrylate glue occlusion (CAE). METHODS: A systematic review was updated and used to construct a Markov decision model. Outcomes were reintervention on the truncal vein, retreatment of residual varicosities and quality-adjusted life years (QALY) and costs over 5 years. RESULTS: UGFS has a significantly greater reintervention rate than other procedures; there is no significant difference between the other procedures. The cost per QALY of EVLA vs UGFS in our base-case model is £16,966 ($23,700) per QALY, which is considered cost effective in the UK. RFA, MOCA, and CAE have greater procedure costs than EVLA with no evidence of greater benefit for patients. CONCLUSIONS: EVLA is the most cost-effective therapeutic option, with RFA a close second, in adult patients requiring treatment in the upper leg for incompetence of the GSV. MOCA, UGFS, CAE, conservative care, and high ligation and stripping are not cost effective at current prices in the UK National Health Service. MOCA and CAE seem to be promising, but further evidence on the effectiveness, reinterventions, and health-related quality of life is needed, as well as how cost effectiveness may vary across settings and reimbursement systems.
引用
- Epstein D, Bootun R, Diop M, et al. Cost-effectiveness analysis of current varicose veins treatments. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34450353. doi:10.1016/j.jvsv.2021.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。